Prostate cancer (PCa) is the most common cancer among men. Metabolic syndrome (MeS) is associated with increased PCa aggressiveness and recurrence. Previously, we proposed C-terminal binding protein 1 (CTBP1), a transcriptional co-repressor, as a molecular link between these two conditions. Notably, CTBP1 depletion decreased PCa growth in MeS mice. The aim of this study was to investigate the molecular mechanisms that explain the link between MeS and PCa mediated by CTBP1. We found that CTBP1 repressed chloride channel accessory 2 (CLCA2) expression in prostate xenografts developed in MeS animals. CTBP1 bound to CLCA2 promoter and repressed its transcription and promoter activity in PCa cell lines. Furthermore, we found that CTBP1 formed a repressor complex with ZEB1, EP300 and HDACs that modulates the CLCA2 promoter activity. CLCA2 promoted PCa cell adhesion inhibiting epithelial-mesenchymal transition (EMT) and activating CTNNB1 together with epithelial marker (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression. Moreover, CLCA2 depletion in PCa cells injected subcutaneously in MeS mice increased the circulating tumor cells foci compared to control. A microRNA (miRNA) expression microarray from PCa xenografts developed in MeS mice, showed 21 miRNAs modulated by CTBP1 involved in angiogenesis, extracellular matrix organization, focal adhesion and adherents junctions, among others. We found that miR196b-5p directly targets CLCA2 by cloning CLCA2 3 0 UTR and performing reporter assays. Altogether, we identified a new molecular mechanism to explain PCa and MeS link based on CLCA2 repression by CTBP1 and miR-196b-5p molecules that might act as key factors in the progression onset of this disease.
Introduction
Prostate cancer (PCa) incidence and mortality rates have been declining since 1990. Nevertheless, PCa is still the most prevalent cancer among men and the second leading cause of cancer death. 1 Age, race and family history are the established risk factors for this disease 2 ; however, there is increasing evidence showing that diet and lifestyle play a crucial role in PCa biology and tumorigenesis. [3] [4] [5] Metabolic syndrome (MeS) is a cluster of pathophysiological disorders that comprises increase in at least three of the following factors: abdominal obesity, triglycerides, cholesterol, blood pressure and glucose. 6 For more than one decade, MeS role in PCa incidence and progression has been studied with different outcomes; nonetheless, recently, a meta-analysis revealed that this disease is associated with poor PCa patient prognosis, increased tumor aggressiveness and biochemical recurrence. 7 In the last years, our group wondered about the mechanism whereby MeS influences PCa. We identified C-terminal binding protein 1 (CTBP1) as a molecular link between these two conditions. CTBP1 is a transcriptional co-repressor of tumor suppressor genes that is activated with much higher affinity by NADH (>100-fold) compared to NAD 1 . 8 Therefore, we generated a MeS mice model by chronically feeding animals with a high fat diet (HFD) and found that CTBP1 depletion in MeS mice dramatically decreased PCa growth. 9, 10 Chloride channel accessory 2 (CLCA2) is a type I integral transmembrane protein. 11 It was proposed as a tumor suppressor in breast and colorectal cancer. [12] [13] [14] Tanikawa et al.
found that CLCA2 expression was remarkably decreased in prostate, breast, bladder, esophageal and lung cancers compared to normal tissues. Particularly in PCa, they established that CLCA2 expression in prostatic intraepithelial neoplasia is similar to normal prostate tissue but higher than invasive tumors. 15 However, CLCA2 role in PCa has not yet been studied. Previously, Elble group showed that CLCA2 is a negative regulator of proliferation 16 and epithelial-mesenchymal transition (EMT) in breast cancer (BrCa). 17 Recently, they reported that CLCA2 is part of two functional adhesion complexes, one with epithelial V-like antigen 1 (EVA1) and zona occludens 1 (ZO-1), and the other with b-catenin (CTNNB1), that are involved in EMT suppression. 18 Also BrCa patients with low CLCA2 expression in primary tumors have more metastasis. 19 In melanoma, Riker et al. demonstrated a negative correlation between a metastatic state and CLCA2 expression. 20 Few reports studied the mechanism for CLCA2 expression regulation. So far, the most important reported inductor is TP53. 15, 16, 21 On the other hand, epigenetic regulation came out as a key factor that represses CLCA2 expression in malignant tissues, 13, 15 but how this is regulated is not fully understood.
The aim of this work was to understand CTBP1 role linking MeS with PCa development and progression. Hence, we examined CTBP1 function in the regulation of CLCA2 transcription and multiple microRNAs (miRNAs) using in vitro and in vivo models.
Materials and Methods
Cell culture, transfections and treatments PC3 (ATCC: CRL-1435), 22Rv1 (ATCC: CRL-2505), LNCaP (ATCC: CRL-1740), C4-2 cell lines and its stable derivatives were grown in RPMI 1640 (Invitrogen) supplemented with 10% of fetal bovine serum (FBS) and antibiotics in a 5% CO 2 humidified atmosphere at 378C. PC3.shCTBP1 and its control (PC3.pGIPZ) stable cell lines were described previously. PC3.shCLCA2 (shCLCA2) and its control PC3.pGIPZ (pGIPZ) cells lines were generated by lentiviral infection as described previously 9 using pGIPZ.shCLCA2 or pGIPZ plasmids. Stable transfected cells were selected with 2 lg/ml of puromycin (Sigma-Aldrich) for 10 days and then maintained with puromycin (1 lg/ml). Cells with CTBP1 or CLCA2 over-expression and its control were generated by transient transfection using polyethylenimine (PEI-PolySciences INC) in a PEI:DNA ratio 2:1. Trichostatin A (TSA, Sigma-Adrich) was used 1 mM for 24 hrs.
Plasmids
CTBP1 plasmid and its control (pcDNA3) were described previously. 10 pGL4 plasmids with different lengths of the CLCA2 promoter, pGIPZ.shCLCA2 and pGIPZ control, pLEX-CLCA2 and pLEX were described previously. 16, 18 ZEB1 plasmids were reported previously, 22 HDACs plasmids were kindly provided by Dr. Martin Monte (Universidad de Buenos Aires, Argentina) and EP300 plasmid was described previously. 23 The 3 0 UTR CLCA2 (1,031 bp) was amplified using specific primers (Supporting Information Table 1 ) and cloned in Spe I and Hind III restriction sites of pMIR-REPORT firefly luciferase vector plasmid (pMIR, Ambion, Grand Island, NY). TOP FLASH plasmid was kindly provided by Jorge Filmus (Sunnybrook Health Sciences Centre, Toronto, Canada).
What's new?
Prostate cancer patients who also have metabolic syndrome often find their cancers more aggressive. A new study examines the molecular link between metabolic syndrome and cancer. According to previous results, a lack of the transcriptional corepressor CTBP1 hinders the growth of prostate cancer. In this study, the authors looked at whether CTBP1 influences expression of the tumor suppressor CLCA2. They found that CTBP1 stopped transcription of CLCA2 by binding to its promoter. In mice with metabolic syndrome given cancers cells that lacked CLCA2, more circulating tumor cells arose than in mice with control tumors, suggesting that suppressing CLCA2 expression promotes EMT.
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Clone was selected by sequencing. Plasmids containing miR196b-5p and miR-196a-5p were kindly provided by Ann-Joy Cheng (Chang Gung University, Taiwan). 24 Luciferase reporter assay PC3 cells were transfected in 12-well plates in triplicate using PEI and 1 mg of each plasmid. After 48 h of transfection, luciferase activity was determined by Luciferase Assay system (Promega) according to the manufacturer's instructions using GloMax 96 Microplate Luminometer (Promega). Data were normalized to total protein determined by Bradford assay.
RNA isolation and RT-qPCR
Total RNA from cells or xenografts was isolated using TRI Reagent (Molecular Research Center) followed by an isopropanol precipitation overnight at 2208C. Retrotranscription (RT) was performed using 2 mg of RNA and RevertAid First Strand kit (Fermentas, Vilnius, Lithuania). Real time quantitative polymerase chain reaction (qPCR) was performed using TAQ Pegasus (Productos Bio-L ogicos, Argentina) in a CFX96 Touch Real-Time PCR Detection System (Bio-Rad). Primers were designed by Primer-BLAST (NIH) and purchased from Macrogen (Supporting Information Table 1) . miRNAs (100 ng) were retrotranscribed using stem-loop method as described previously. 25 Specific stem loop primer for each miRNA was used in RT. Primers for qPCR were the universal reverse primer complementary to the stem loop, and a specific forward primer (Supporting Information Table 1 ).
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed from PC3 cells using anti-CTBP1 or anti-GAL4 non-specific control antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA), as described previously. 9 ChIP-DNA was amplified by qPCR using primers mapping at 1,165 bp upstream from CLCA2 transcription start site (TSS), or 200 bp upstream from the HBB TSS (Supporting Information Table 1 ). Fold enrichment was calculated normalizing data to input and GAL4.
Cell adhesion assay
Cell adhesion assay was performed as described previously with some modifications. 26 Briefly, after transfections, cells were attached to 96-well plate for 30 min. Media was removed and the attached cells were washed twice with phosphate-buffered saline (PBS), fixed with methanol and stained with crystal violet for 10 min. After two washes with water, stain was dissolved in 10% methanol: 5% acetic acid and absorbance at 620 nm was determined with enzymelinked immunosorbent assay Multiskan FC (Thermo Scientific).
PCa and MeS mice
Animal model was generated as described previously. 9, 10 Briefly, 4 weeks old male nu/nu mice (N 5 24), were randomized into two groups, fed with control diet (CD) or HFD and housed under pathogen free conditions following IBYME's animal care guidelines. Mice were fed ad libitum with CD (3120 kcal/kg, 5% fat, n 5 22) or HFD (4520 kcal/kg, 37% fat, n 5 22) generated supplementing chow food with 32% of bovine fat first juice (Fatty, Buenos Aires, Argentina). After 12 weeks of diet, each group was randomly divided in two subgroups and subcutaneously (s.c.) injected with PC3.pGIPZ or PC3.shCLCA2 stable cells (4.8 3 10 6 ). Body weight was monitored once a week and tumor size was measured three times a week. Forty days after injection, animals were sacrificed and tumors and soft tissues (lung and liver) were excised. Peripheral blood was collected by cardiac puncture from each mice in a tube containing 60 ll of ethylene diamine tetraacetic acid 0.5 M pH 8.
CTC assay
To recover circulating tumor cells (CTCs) from peripheral blood, blood cells were obtained by centrifugation and hemolyzed by ammonium chloride potassium buffer incubations (3 3 7 min; 1 3 5 min). Cells were washed with PBS and resuspended in RPMI medium supplemented with 10% FBS, antibiotics and puromycin (1 lg/ml). Cells were seeded on 12-well plates and medium was replaced every 5 days. After 15 days, CTCs were photographed with a Q-Color5 Digital Camera (OLYMPUS).
Microarray analysis
mRNA microarray was reported previously. 9 RNA obtained from those tumors was hybridized with GeneChip miRNA 4.0 (Affymetrix). Data normalization and analysis were made as described previously. 10 Microarray data have been deposited in GEO database (Accession number: GSE104119). Upregulated miRNAs by CTBP1 with FC > 1.5 (p < 0.05) and signal >5 were selected. Potential miRNA target genes with at least three hits, Gene Ontology (GO) and pathways analysis were determined using ChemiRs database.
Statistical analysis
All results are given as mean and SD of three independent experiments unless stated otherwise. Student t-tests or twoway analysis of variance followed by Tukey test were performed. Shapiro-Wilk and Levene tests were used to assess normality and homogeneity of variances. *p< 0.05; **p< 0.01; ***p< 0.001.
Results

CTBP1 and MeS repress CLCA2 expression
We reported previously a microarray analysis generated from CTBP1-depleted expression or control xenografts grown in MeS mice. 9 In this work, we focused our study on the olfactory signaling pathway obtained from the microarray gene set enrichment analysis (GSEA) (Fig. 1a) . We found that CTBP1 significantly repressed four genes from this pathway: OR4C45, OR5P2, GUCA1C and CLCA2 (Fig. 1b) . Due to CLCA2 involvement in tumor suppression, we further
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investigated CLCA2 role in PCa and MeS. We first validated microarray results by RT-qPCR from xenografts generated with PC3.shCTBP1 or control stable cells in CD or HFD fed mice. As shown in Figure 1c , we observed CLCA2 induction after CTBP1 depletion in MeS conditions, validating microarrays findings. Next, we determined CLCA2 expression in a panel of PCa cell lines (Fig. 1d) . We found that androgensensitive LNCaP cells and the androgen-insensitive PC3 cells showed higher CLCA2 expression compared to 22Rv1 and C4-2 PCa cells lines.
CTBP1 represses CLCA2 transcription in PC3 cell line
To further investigate CLCA2 expression regulation by CTBP1, reporter constructs containing different length of CLCA2 promoter regions (-3,565 bp to 11 bp from the TSS) were co-transfected with CTBP1 or control (pcDNA3) plasmids into PC3 cell line. CTBP1 significantly repressed the activity of all the different CLCA2 promoter regions (Fig. 2a) . The 21182 to 11 fragment showed the highest CLCA2 promoter activity and it was used in the subsequent experiments (Fig. 2a) . Accordingly to reporter results, we found that CTBP1 repressed CLCA2 mRNA levels in PC3 cells (Figs. 2b and 2c) . Additionally, using ChIP, we determined that CTBP1 bound to the CLCA2 proximal promoter region (Fig. 2d) . Hence, CTBP1 associates to CLCA2 promoter and represses its transcription in PC3 cell line.
CLCA2 is epigenetically regulated by HDACs, ZEB1 and EP300
To determine potential transcription factors (TFs) that coregulate with CTBP1 CLCA2 transcription, we cotransfected CLCA2 reporter with CTBP1 expression plasmid plus a panel of TFs selected from the literature that potentially bind to CLCA2 promoter or interacts with CTBP1 protein. We found that E2F1, STAT3, RELA and EP300 had no effect on CLCA2 promoter activity; however, TP53, BRCA1, ETS2 and ZEB1 induced its activity in PC3 cell line (Figs. 3a and 3b and Supporting Information Fig. 1 ). Moreover, we observed that CLCA2 promoter activity repression by CTBP1 was synergistically increased in the presence of EP300 and ZEB1 (Figs. 3a and 3b) .
Furthermore, we assessed HDACs role on CLCA2 transcription regulation by CTBP1. We observed that HDAC1 and HDAC2 had no effect on CLCA2 transcription regulation; whereas HDAC3, HDAC4 and HDAC6 repressed its activity ( Figs. 3c and 3d; Supporting Information Fig. 1 ). CTBP1 synergistically repressed with HDAC2 and HDAC3 the CLCA2 promoter activity (Figs. 3c and 3d) . Notably, the HDAC inhibitor, TSA, induced CLCA2 promoter activity and mRNA levels in PC3 cells (Figs. 3e and 3f) . Altogether, these results show for the first time multiple TFs and epigenetic co-regulators that modulate CLCA2 gene expression in PCa.
CLCA2 induces cell adhesion and epithelial phenotype
To more deeply understand CLCA2 function in PCa, we generated PCa cells with CLCA2 depleted or overexpressed and verified its expression (Fig. 4a) . We next performed cell adhesion assays in a panel of PCa cell lines including CLCA2 modulated expression cells. Interestingly, CLCA2 overexpression promoted cell adhesion in all PCa cell lines, and CLCA2 depletion significantly decreased it in PC3 cells (Fig.  4b) . Hence, CLCA2 plays a role increasing cell adhesion, the initial step for invasion and metastasis.
Based on previous reports, 17, 18 we investigated CLCA2 role in EMT and CTNNB pathways modulation in PCa. To assess the transcriptional activity of CTNNB, we used TOP FLASH reporter plasmid using PC3.shCLCA2 and control (pGIPZ) cells. Interestingly, CLCA2 depletion significantly induced CTNNB activation (Fig. 4c) . In addition, CLCA2 depletion dramatically repressed the expression of the epithelial marker CDH1, with concomitant induction of the mesenchymal markers expression; SNAI2 and TWIST1, compared to control (Fig. 4d) . CDH2, SNAI1, VIM, ZEB1 and CTNNB did not show expression changes in these conditions (data not shown).
To understand CLCA2 role in PCa associated to MeS, we injected s.c. PC3.shCLCA2 or PC3.pGIPZ control cell lines in CD or HFD fed mice. No significant differences were observed in tumor volume between CLCA2 depleted and control groups (Supporting Information Fig. 2) . However, based 
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on CLCA2 role in PCa cell adhesion and EMT, we recovered CTCs from the peripheral blood of these mice in a clonogenic assay. We found that CLCA2 depletion increased the percentage of mice with CTC foci compared to pGIPZ control mice (Fig. 4e) . No sign of micro-or macro-metastasis were observed in soft tissues (lung and liver) by hematoxylin and eosin stains from all groups (data not shown).
Altogether, these results propose a novel mechanism for CTBP1 function linking PCa and MeS. Thus, CTBP1 represses the epithelial gene promoter CLCA2, which in turn, induces mesenchymal markers and might promote metastasis.
CTBP1 regulates multiple miRNAs in PCa associated to MeS
To increase the knowledge about the molecular mechanisms for CTBP1 role linking PCa and MeS, we assessed miRNAs regulation by CTBP1 in tumors from MeS mice. We hybridized miRNA expression microarrays with miRNAs isolated from xenografts described in Figure 1a . After data normalization, we obtained 21 miRNAs regulated by CTBP1 (Fig. 5a) . Interestingly, after GO and pathways analysis, we observed that these miRNAs modulated by CTBP1 are implicated in angiogenesis, extracellular matrix organization, developmental biology, cancer pathways, focal adhesion and adherents junctions among others (Figs. 5b and 5c ).
miR-196b-5p targets CLCA2 and modulates cell adhesion
To predict CTBP1 regulated miRNAs that potentially target CLCA2, we performed a supervised analysis. From the 21 miRNAs in Figure 5a , we selected the CTBP1-upregulated miRNAs that might repress CLCA2 (positive fold change) and determined the predicted target genes using ChemiRs Figure 3 . CLCA2 is epigenetically regulated by HDACs, ZEB1 and EP300. (a-d) PC3 cells were cotransfected with the CLCA2 promoter reporter (-1,182/11) and CTBP1 or control (pcDNA3) plasmids plus ZEB1, EP300, HDAC2 or HDAC3, and Luciferase activity was determined. The mean of two independent experiments with three replicates and SD is plotted. (e) PC3 cells were exposed to TSA (1 mM) and cotransfected with CLCA2 promoter reporter (-1,182/11) and Luficerase activity was determined. (f) mRNA CLCA2 levels measured by RTqPCR of PC3 cells treated with TSA 1 mM. (http://omics.biol.ntnu.edu.tw/ChemiRs/). All the miRNAs that have CLCA2 as target by at least two databases with different algorithms were selected (Supporting Information Table 2 , column 1 and 2). Seven miRNAs detailed in Supporting Information Table 2 (column 3 and 4) were analyzed by miRCancer (http://mircancer.ecu.edu/) database. Based on this and literature, we selected miR-196b-5p as a candidate that targets CLCA2.
To validate whether miR-196b-5p targets CLCA2 mRNA, we cloned CLCA2 3 0 UTR region downstream of the luciferase gene in a pMIR-REPORT plasmid. We cotransfected CLCA2 3 0 UTR and miR-196b, miR-196a or control plasmids in PC3 cells and found that miR-196a and miR-196b decreased luciferase activity demonstrating for the first time that CLCA2 is targeted by these miRNAs in PCa (Fig. 5d) .
Next, we validated the miRNA microarray result by determining miR-196b-5p expression from xenografts generated in MeS or control mice after CTBP1 depletion. Accordingly, CTBP1 depletion significantly decreased miR-196b-5p expression compared to control only in HFD fed mice (Fig. 5e) . Finally, to understand miR-196b-5p role in PCa, we evaluated its effect on cell adhesion. Accordingly, we found that miR196b decreased cell adhesion compared to control or miR196a (Fig. 5f) . Thus, miR-196b-5p emerged as a critical miRNA regulated by CTBP1, suggesting a potential link for PCa progression in MeS.
Discussion
In this work, we explored the mechanism underlying CTBP1 role in the modulation of PCa progression associated with MeS. We demonstrated that CTBP1 represses CLCA2 in PCa xenografts developed in MeS mice. Moreover, we found that CTBP1 binds to CLCA2 proximal promoter region and represses its transcription together with ZEB1, EP300 and HDACs in PCa cell lines. It was reported previously that CTBP1 forms a repressor complex with these co-regulators 8, 27 ; nevertheless, we described here for the first time this co-regulation at the CLCA2 promoter. Epigenetic repression of CLCA2 by gene promoter hypermethylation has already been described 13, 15 ; however, we showed here that CLCA2 is regulated by TSA, highlighting the importance of the epigenetic modifications in the CLCA2 expression regulation. In addition, we tested a panel of TFs that directly regulated CLCA2: TP53, BRCA1 and ETS2; or TFs that had no effect on CLCA2 promoter activity: E2F1, STAT3, RELA and EP300. Overall, our data demonstrated novel mechanisms for CLCA2 transcriptional regulation in PCa.
Regarding CLCA2 function in PCa cells, we demonstrated that CLCA2 is an EMT modulator. In particular, we showed that CLCA2 promotes cell adhesion, inducing epithelial markers (CDH1) and repressing mesenchymal genes (SNAI2 and TWIST1). Notably, CLCA2 depletion significantly activated CTNNB TF function. These results are consistent with the reports in BrCa that showed CLCA2 promoted an epithelial phenotype by sequestering CTNNB in the membrane and repressing EMT genes 17, 18 (Fig. 6) . This is the first report showing CLCA2 as an EMT inhibitor in PCa.
In this work, we also assessed the CLCA2 role in vivo. We found that CLCA2 depleted xenografts generated in MeS mice promoted CTCs release in a higher percentage of mice compared to CLCA2 control expression xenografts. Although CLCA2 expression modulation did not affect PCa growth, these results reinforces the idea that CLCA2 loss promotes EMT. Moreover, all these findings propose a novel mechanism for CTBP1 oncogenic role through CLCA2 modulation.
We also described for the first time that CTBP1 modulates multiple miRNAs in PCa from MeS mice that are involved in several pathways related to cancer development and progression. The importance of miRNAs in PCa has already been widely reported 28 ; however, there are few reports showing Figure 6 . Hypothetical model. CTBP1 protein assembles to CLCA2 proximal promoter region together with EP300, ZEB1, HDAC2 and HDAC3, and represses its transcription. In addition, CTBP1 induces miR-196b-5p which, in turn represses CLCA2 expression. Hence, CLCA2 promotes an epithelial phenotype by sequestering CTNNB in the membrane and repressing EMT genes.
miRNA modulation by CTBP1. Indeed, our group demonstrated that CTBP1 modulates several miRNAs in BrCa, 10 and Chakravarthi et al. showed that CTBP1 modulates miR-124 in a PCa cell line. 29 Therefore, our results provide a new insight into CTBP1 mechanisms leading to tumor progression in PCa.
Importantly, this is the first report describing miRNAs that target CLCA2 3 0 UTR in PC3 cells. Based on bioinformatic analysis, literature and experimental validation, we selected miRNA-196b-5p as an important oncomiR up regulated in several cancers that is involved mainly in metastasisrelated processes. 30, 31 In addition, it was recently reported that miRNA-196b-3p overexpression promoted tumor development in a castration resistant PCa mice model. 32 Here, we found that miR-196b-5p is induced by CTBP1 in tumors from MeS mice, targets CLCA2 and inhibits cell adhesion. Although miR-196a is also targeting CLCA2, this miRNA was not regulated by CTBP1 and also it did not regulate cell adhesion.
In summary, we defined a mechanism for CTBP1 oncogenic role in PCa associated with MeS, which involves CLCA2 and miR-196b-5p (see hypothetical model Fig. 6 ). More studies are necessary to establish CLCA2 and miR196b-5p as biomarker candidates for these diseases.
